Whole chromosome alterations predict survival in high-risk neuroblastoma without MYCN amplification

Clinical Cancer Research

Volumn 14, Issue 17, 2008, Pages 5540-5547

  Bilke, Sven ^a   Chen, Qing Rong ^a,b   Wei, Jun S ^a   Khan, Javed ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEIC ACID BINDING PROTEIN; PROTEIN MYCN; UNCLASSIFIED DRUG; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

ARTICLE; CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME MUTATION; COMPARATIVE GENOMIC HYBRIDIZATION; GENE AMPLIFICATION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NEUROBLASTOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; CHROMOSOME ABERRATION; GENE DOSAGE; GENETICS; PILOT STUDY; SURVIVAL; TIME;

CHROMOSOME ABERRATIONS; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PILOT PROJECTS; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 53049092770     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4461     Document Type: Article

References (27)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-20.
2. Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr 2005;17:7-13.
3. Pearson AD, Phillip T. Prognosis of low-risk and high- risk neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA, editors. Neuroblastoma. Amsterdam: Elsevier Science; 2000. p. 555.
4. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165-73.
5. Brodeur GM, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 895-937.
6. London WB, Castleberry RP, Matthay KK, et al. Evi- dence for an age cutoff greater than 365 days forneuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005;23:6459-65.
7. Chen QR, Bilke S, Wei JS, et al. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma. BMC Genomics 2004;5:70.
8. Plantaz D,Vandesompele J,Van Roy N, et al. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11Q deletion in tumors lacking MYCN amplification. Int J Cancer 2001;91:680-6.
9. Selzer RR, Richmond TA, Pofahl NJ, et al. Analysis of chromosome breakpoints in neuroblastoma at sub- kilobase resolution using fine-tiling oligonucleotide array CGH. Genes Chromosomes Cancer 2005;44:305-19.
10. Vandesompele J, Speleman F, Van Roy N, et al. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: How many genetic subgroups are there? Med Pediatr Oncol 2001;36:5 -10.
11. Mosse YP, Diskin SJ, Wasserman N, et al. Neuroblastomas have distinct genomic DNAprofiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer 2007;46:936 -49.
12. Chen YX, Stallings RL. Differential patterns of micro RNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 2007;67:976-83.
13. Asgharzadeh S, Pique-Regi R, Sposto R, et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN geneamplification. J Natl Cancer Inst 2006;98:1193-203.
14. Oberthuer A, Berthold F,Warnat P, et al. Customized oligonucleotide microarray gene expression based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006;24:5070-8.
15. Ohira M, Oba S, NakamuraY, et al. Expression profiling using a tumor-specific cDN Amicroarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 2005;7:337 -50.
16. Schramm A, Vandesompele J, Schulte JH, et al. Translating expression profiling into a clinically feasible test to predict neuroblastoma outcome. Clin Cancer Res 2007;13:1459 -65.
17. Wei JS, Greer BT, Westermann F, et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 2004;64:6883 -91.
18. Bowman LC, Castleberry RP, CantorA, et al. Genetic staging of unresectable or metastatic neuroblasto- ma in infants: A Pediatric Oncology Group Study. J Natl Cancer Inst1997;89:373 -80.
19. Attiyeh EF, London WB, MosseYP, et al. Chromo-some1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353:2243 -53.
20. Attiyeh EF, MosseYP,Wang Q, et al. Chromosome arm 11q deletion predicts for neuroblastoma outcome: A Children's Oncology Group study. J Clin Oncol 2005;23:6S.
21. Tomioka N, Oba S, Ohira M, et al. Novel risk stratification of patients with neuroblastoma bygenomicsig- nature, which is independent of molecular signature. Oncogene 2007;27:441 -9.
22. Bilke S, Chen QR, Westerman F, Schwab M, Catchpoole D, Khan J. Inferring a tumor progression model for neuroblastoma from genomic data. J Clin Oncol 2005;23:7322 -31.
23. Bilke S, Chen QR,Whiteford CC, Khan J. Detection of low level genomic alterations by comparative genomic hybridization based on cDNA micro-arrays. Bioinformatics 2005;21:1138-45.
24. George RE, London WB, Cohn SL, et al. Hyper- diploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: A Pediatric Oncology Group Study. J Clin Oncol 2005;23:6466-73.
25. Chen QR, Bilke S, Wei JS, et al. Increased WSB1 copy number correlates with its over-expression which associates with increased survival in neuroblastoma. Genes Chromosomes Cancer 2006;45:856-62.
26. Nowell PC. Clonal evolution of tumor-cell populations. Science1976;194:23 -8.
27. Warnat P, Oberthuer A, Fischer M, Westermann F, Eils R, Brors B. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes. BMC Cancer 2007;7:89.